Results 71 to 80 of about 1,181,836 (211)

Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials.

Gastroenterology
BACKGROUND AND AIMS CT-P13 subcutaneous (SC), an SC formulation of the intravenous (IV) infliximab biosimilar CT-P13 IV, creates a unique exposure profile. We aimed to demonstrate superiority of CT-P13 SC versus placebo as maintenance therapy in patients
Stephen B. Hanauer, B. Sands, S. Schreiber, S. Danese, M. Kłopocka, J. Kierkuś, R. Kulynych, Maciej Gonciarz, A. Sołtysiak, Patryk Smoliński, Slobodan Srećković, E. Valuyskikh, A. Lahat, M. Horyński, A. Gasbarrini, M. Osipenko, V. Borzan, M. Kowalski, D. Saenko, R. Sardinov, Sang Joon Lee, Sunghyun Kim, Yunju Bae, Sunhee Lee, Seulgi Lee, J. Lee, S. Yang, Jimin Lee, Juhyun Lee, Jong Min Kim, G. Park, W. Sandborn, J. Colombel   +32 more
semanticscholar   +1 more source

Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand.

Immunotherapy, 2023
Background: The infliximab biosimilar CT-P13 was approved in Thailand in 2015. Methods: This open-label, multicenter, post-marketing surveillance study evaluated the safety (events of special interest [ESIs]; primary end point) and effectiveness of 46 ...
A. Mahakkanukrauh, S. Chaiamnuay, A. Koolvisoot, Tassanee Kitamnuayphong, Siriporn Manavathongchai, M. Osiri, W. Louthrenoo, P. Uea-areewongsa, K. Ahn, N. Jung, Minkyun Kim, Seulgi Lee, Hanna Kim, Sunghyun Kim   +13 more
semanticscholar   +1 more source

Position Paper Português Sobre o Uso de Biossimilares na Psoríase [PDF]

, 2016
info:eu-repo/semantics ...
Ferreira, A., Ferreira, P., Filipe, P., Henriques, M., Leite, L., Magina, S., Marques-Pinto, G., Massa, A., Oliveira, H., Selores, M., Sousa-Basto, A., Tavares-Bello, R., Torres, T., Varela, P.   +13 more
core   +2 more sources

Comparative effectiveness of the biosimilar CT-P13

Journal of Comparative Effectiveness Research, 2017
The first biosimilar infliximab, CT-P13 (infliximab-dyyb) has been used for the treatment of inflammatory diseases for 4 years. CT-P13 has highly similar efficacy and safety profiles with a lower price than the originator infliximab and has been approved in 81 countries.
openaire   +2 more sources

Evaluation of novel cardiovascular risk calculators in patients with rheumatoid arthritis

Journal of Rheumatic Diseases
Objective: CT-P13, a biosimilar of infliximab, is widely used for treating ankylosing spondylitis (AS). However, the formation of anti-drug antibodies (ADAs) can reduce its efficacy.
Dionicio Angel Galarza-Delgado, Valeria Gonzalez-Gonzalez, Natalia Guajardo-Jauregui, Jesus Alberto Cardenas-de la Garza, Rosa Icela Arvizu-Rivera, Maria Fernanda Elizondo-Benitez, Andrea Lizbeth Guajardo-Aldaco, Jose Ramon Azpiri-Lopez, Iris Jazmin Colunga-Pedraza   +8 more
doaj   +1 more source

Efficacy of Infliximab Biosimilar CT-P13 Induction Therapy on Mucosal Healing in Ulcerative Colitis [PDF]

Journal of Crohn's and Colitis, 2016
CT-P13 is the first biosimilar to infliximab that has been approved for the same indications as its originator infliximab. No data are available on the effect of infliximab biosimilar on mucosal healing. The aim of this study was to evaluate the efficacy of CT-P13 induction therapy on mucosal healing in patients with ulcerative colitis [UC].UC patients,
Farkas, Klaudia, Rutka, Mariann, Golovics, Petra A., Végh, Zsuzsanna, Lovász, Barbara D., Nyári, Tibor, Gecse, Krisztina B., Kolar, Martin, Bortlik, Martin, Duricova, Dana, Machkova, Nadezda, Hruba, Veronika, Lukas, Martin, Mitrova, Katarina, Malickova, Karin, Bálint, Anita, Nagy, Ferenc, Bor, Renáta, Milassin, Ágnes, Szepes, Zoltán, Palatka, Károly, Lakatos, Péter L., Lukas, Milan, Molnár, Tamás   +23 more
openaire   +4 more sources

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results [PDF]

, 2017
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological therapy,
Argüelles Arias, Federico, Castro Laria, Luisa, Guerra Veloz, María Fernanda, Maldonado Pérez, Belén, Merino Bohórquez, Vicente, Perea Amarillo, Raúl, Romero Gómez, Manuel, Vilches Arenas, Ángel   +7 more
core  

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model. [PDF]

, 2016
BACKGROUND: Ulcerative colitis (UC) is the most common form of inflammatory bowel disease in the UK. UC can have a considerable impact on patients' quality of life. The burden for the NHS is substantial. OBJECTIVES: To evaluate the clinical effectiveness
Archer, R., Basarir, H., Cantrell, A., Carroll, C., Harvey, R., Hoque, S., Lobo, A., Martyn-St James, M., Ren, S., Stevens, J., Tappenden, P.   +10 more
core   +2 more sources

Longitudinal Phenotypic Trajectories in GNAO1‐Related Disorders: Defining Disease Progression and Clinical Profiles

Annals of Neurology, EarlyView.
Objective Pathogenic variants in GNAO1 cause a spectrum of epilepsy, movement disorders, and developmental impairment. Clinical heterogeneity complicates prognosis and therapeutic development. We present the first longitudinal natural history study of GNAO1‐related disorders (GNAO1‐RD) to delineate phenotypic trajectories. Methods Sixty‐six individuals
Jana Domínguez‐Carral, Ana María Domínguez Cobo, Sol Balsells, Anna Aguilar‐Ros, Chu‐Ting Chang, William G. Ludlam, Kathryn Yang, Katerina Bernardi, Micaela Chinigioli, Ainara Salazar‐Villacorta, Veronica Di Pisa, Nuria Lamagrande‐Casanova, Elena González‐Alguacil, Beatriz De la Casa‐Fages, Akihisa Okumura, Josefina Rodríguez, Ayush Agarwal, Daniela Muñoz‐Chesta, Carolina Reynoso‐Osnayo, Amy Lin, Brahim Tabarki, Jobaida Parvin, Adolfo Alberto Gallo, Andreia Forno, Fabian Maass, Johnny Montiel Blanco, Salomé Nasif, Elizabeth Jennions, Jorge Luis Ramón‐Gómez, Helene Verhelst, Juan José Nieto Barceló, Dunja Čokolić Petrović, Luz Victoria García Ruiz, Christoph van Riesen, Paulo Rego Sousa, Maria del Pilar Massaro Sanchez, Husnea Ara Khan, Wejdan Hakami, Jennifer Friedman, Iván Espinoza‐Quinteros, Monica Troncoso, Divyani Garg, Micaela Pauni, Hirokazu Kurahashi, María Concepción Miranda‐Herrero, Anna Duat‐Rodriguez, Luca Soliani, Manju A. Kurian, Angeles Schteinschnaider, Siddharth Srivastava, Darius Ebrahimi‐Fakhari, Kirill A. Martemyanov, Juan Darío Ortigoza‐Escobar   +52 more
wiley   +1 more source

Fluorine‐18‐Labeled Nucleotide Analogs Targeting Ecto‐5'‐Nucleotidase (CD73) for Positron Emission Tomography Imaging of Solid Tumors

Angewandte Chemie, Volume 138, Issue 17, 20 April 2026.
Fluorine‐18‐labeled CD73 inhibitor [18F]PSB‐19427 enables noninvasive PET mapping of CD73 overexpression in triple‐negative breast (TNBC) and pancreatic cancer. For [18F]PSB‐19427, specific binding in human tumor tissues, favorable biodistribution with prolonged blood retention, robust tumor uptake, and superiority to [18F]FDG in a TNBC model ...
Clemens Dobelmann, Constanze C. Schmies, Georg Wilhelm Rolshoven, Mirko Scortichini, Stefan Wagner, Andreas Isaak, Riham M. Idris, Jennifer Dabel, Lucie Grey, Karolina Losenkova, Susanne Moschütz, Haneen Al Hroub, Antje Keim, Sandra Höppner, Jouko Sandholm, Pia Boström, Maija Hollmén, Norbert Sträter, Sven Hermann, Gennady G. Yegutkin, Kenneth A. Jacobson, Sonja Schelhaas, Christa E. Müller, Anna Junker   +23 more
wiley   +2 more sources